Effects of benralizumab in patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps
C. Santomasi (Bari, Italy), E. Buonamico (Bari, Italy), S. Dragonieri (Bari, Italy), E. Lulaj (Bari, Italy), L. Maselli (Bari, Italy), I. Iorillo (Bari, Italy), S. Piccinno (Bari, Italy), A. Capuano (Bari, Italy), M. Ahroud (Bari, Italy), I. Dei Lazzaretti (Bari, Italy), L. Iannuzzi (Bari, Italy), G. Carpagnano (Bari, Italy)
Source: International Congress 2022 – Studies targeting IL-5 pathways in asthma
Session: Studies targeting IL-5 pathways in asthma
Session type: Thematic Poster
Number: 2131
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Santomasi (Bari, Italy), E. Buonamico (Bari, Italy), S. Dragonieri (Bari, Italy), E. Lulaj (Bari, Italy), L. Maselli (Bari, Italy), I. Iorillo (Bari, Italy), S. Piccinno (Bari, Italy), A. Capuano (Bari, Italy), M. Ahroud (Bari, Italy), I. Dei Lazzaretti (Bari, Italy), L. Iannuzzi (Bari, Italy), G. Carpagnano (Bari, Italy). Effects of benralizumab in patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. 2131
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|